Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 30Lymphoma, Follicular 9Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Lymphoma, Non-Hodgkin 5Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 3Smoldering Multiple Myeloma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Burkitt Lymphoma 2Recurrence 1Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

ibrutinib 1fludarabine phosphate 1Rituximab 1Pharmacogenomic Testing 1Lenalidomide 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Lenalidomide × 30 days × Clear all
NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡